Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

A Protective Role of Aryl Hydrocarbon Receptor Repressor in Inflammation and Tumor Growth.

Vogel CFA, Ishihara Y, Campbell CE, Kado SY, Nguyen-Chi A, Sweeney C, Pollet M, Haarmann-Stemmann T, Tuscano JM.

Cancers (Basel). 2019 Apr 27;11(5). pii: E589. doi: 10.3390/cancers11050589.

2.

Infectious risks associated with medicinal Cannabis: Potential implications for immunocompromised patients?

McHardy I, Romanelli A, Harris LJ, Opp G, Gaudino R, Torres A, Polage CR, Tuscano JM, Thompson GR 3rd.

J Infect. 2018 May;76(5):500-501. doi: 10.1016/j.jinf.2018.01.010. Epub 2018 Feb 13. No abstract available.

PMID:
29408325
3.

A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation.

Barisone GA, O'Donnell RT, Ma Y, Abuhay MW, Lundeberg K, Gowda S, Tuscano JM.

PLoS One. 2018 Jan 5;13(1):e0190860. doi: 10.1371/journal.pone.0190860. eCollection 2018.

4.

Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.

Witzig TE, Luigi Zinzani P, Habermann TM, Tuscano JM, Drach J, Ramchandren R, Kalayoglu Besisik S, Takeshita K, Casadebaig Bravo ML, Zhang L, Fu T, Goy A.

Am J Hematol. 2017 Oct;92(10):E575-E583. doi: 10.1002/ajh.24854. Epub 2017 Aug 28.

5.

Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia.

Yoshida S, Tuscano E, Duong C, Chung J, Li Y, Beckett L, Tuscano JM, Satake N.

Leuk Lymphoma. 2017 May;58(5):1254-1257. doi: 10.1080/10428194.2016.1235273. Epub 2016 Oct 5. No abstract available.

6.

The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.

Abuhay M, Kato J, Tuscano E, Barisone GA, Sidhu RS, O'Donnell RT, Tuscano JM.

Cancer Immunol Immunother. 2016 Oct;65(10):1169-75. doi: 10.1007/s00262-016-1873-y. Epub 2016 Aug 9.

PMID:
27506529
7.

Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.

Satake N, Duong C, Yoshida S, Oestergaard M, Chen C, Peralta R, Guo S, Seth PP, Li Y, Beckett L, Chung J, Nolta J, Nitin N, Tuscano JM.

Mol Med. 2016 Oct;22:632-642. doi: 10.2119/molmed.2015.00210. Epub 2016 Jul 22.

8.

A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.

Kirschbaum MH, Frankel P, Synold TW, Xie Z, Yen Y, Popplewell L, Chen R, Aljitawi O, Tuscano JM, Chan KK, Newman EM.

Leuk Lymphoma. 2016 Oct;57(10):2307-14. doi: 10.3109/10428194.2016.1146947. Epub 2016 Feb 19.

9.

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.

Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH.

Br J Haematol. 2015 Nov;171(4):530-8. doi: 10.1111/bjh.13634. Epub 2015 Sep 7.

10.

Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.

Kong Y, Barisone GA, Sidhu RS, O'Donnell RT, Tuscano JM.

Mol Med. 2015 Nov;21(1):824-832. doi: 10.2119/molmed.2015.00032. Epub 2015 Aug 24.

11.

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ.

J Clin Oncol. 2015 Jun 10;33(17):1936-42. doi: 10.1200/JCO.2014.57.8138. Epub 2015 Apr 20.

12.

Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.

Kong Y, Barisone GA, Abuhay M, O'Donnell RT, Buksh Z, Yousefian F, Tuscano JM.

Leuk Res. 2014 Nov;38(11):1320-6. doi: 10.1016/j.leukres.2014.08.014. Epub 2014 Aug 30.

PMID:
25241275
13.

Adverse health effects of marijuana use.

Thompson GR 3rd, Tuscano JM.

N Engl J Med. 2014 Aug 28;371(9):878-9. doi: 10.1056/NEJMc1407928. No abstract available.

PMID:
25162901
14.

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators.

Br J Haematol. 2014 Nov;167(4):466-77. doi: 10.1111/bjh.13061. Epub 2014 Aug 8.

15.

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.

Tuscano JM, Dutia M, Chee K, Brunson A, Reed-Pease C, Abedi M, Welborn J, O'Donnell RT.

Br J Haematol. 2014 May;165(3):375-81. doi: 10.1111/bjh.12755. Epub 2014 Mar 7.

PMID:
24606326
16.

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.

Wang M, Popplewell LL, Collins RH Jr, Winter JN, Goy A, Kaminski MS, Bartlett NL, Johnston PB, Lister J, Fanning SR, Tuscano JM, Beck JT, Kaya H, Robeva A, Fan J, Klimovsky J, Cheung W, Cherfi A, O'Connor OA.

Br J Haematol. 2014 May;165(4):510-8. doi: 10.1111/bjh.12780. Epub 2014 Mar 2.

17.

Diagnosis and classification of autoimmune hemolytic anemia.

Bass GF, Tuscano ET, Tuscano JM.

Autoimmun Rev. 2014 Apr-May;13(4-5):560-4. doi: 10.1016/j.autrev.2013.11.010. Epub 2014 Jan 11. Review.

PMID:
24418298
18.

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.

Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM, Newman EM.

Leuk Lymphoma. 2014 Oct;55(10):2301-4. doi: 10.3109/10428194.2013.877134. Epub 2014 Feb 24.

19.

Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.

Vose JM, Habermann TM, Czuczman MS, Zinzani PL, Reeder CB, Tuscano JM, Lossos IS, Li J, Pietronigro D, Witzig TE.

Br J Haematol. 2013 Sep;162(5):639-47. doi: 10.1111/bjh.12449. Epub 2013 Jul 9.

PMID:
23834234
20.

Targeting CD22 in B-cell malignancies: current status and clinical outlook.

Sullivan-Chang L, O'Donnell RT, Tuscano JM.

BioDrugs. 2013 Aug;27(4):293-304. doi: 10.1007/s40259-013-0016-7. Review.

PMID:
23696252

Supplemental Content

Loading ...
Support Center